Novavax boosted on RSV trial results; Medicines Co. says PhIII Oritavancin study a success; Ultragenyx cites positive PhII results for rare disease drug;

 @FierceBiotech: Researchers spotlight two cases of eradicated HIV infection. Story | Follow @FierceBiotech

 @JohnCFierce: FDA cuts the regulatory fuse on Roche's heir to Rituxan. More | Follow @JohnCFierce

 @RyanMFierce: GlaxoSmithKline, J&J make early progress with monthly HIV combo. News | Follow @RyanMFierce

 @EmilyMFierce: Texas A&M launches multimillion-dollar genomics research project. Item | Follow @EmilyMFierce

> Novavax ($NVAX) shares were boosted slightly by upbeat data from an early-stage trial of its RSV vaccine. Report

> Ultragenyx, a startup focused on rare diseases, says it has nabbed positive interim results from a Phase II study of UX001 in 47 patients with hereditary inclusion body myopathy, a progressive muscle-wasting disease. Release

> Jason Rhodes has been promoted to president of Epizyme, which recently pulled off a hot IPO. Rhodes will continue as CFO, reporting to CEO Robert Gould. Release

> Biogen Idec ($BIIB) and Swedish Orphan Biovitrum AB presented new findings for their long-lasting recombinant factor IX candidate Alprolix for hemophilia B. Release

Medical Device News

 @FierceMedDev: Device tax opponents may have gained their opening. Item | Follow @FierceMedDev

 @MarkHFierce: Give us your FMD Fierce 15 nominations today. And spread the word.... More | Follow @MarkHFierce

 @DamianFierce: GI Dynamics has raised $52.2M to get its anti-obesity device through the FDA process. Story | Follow @DamianFierce

> Philips brings updated interventional X-ray system to U.S. market. News

> Clock ticking on vaginal mesh lawsuits against J&J, others. Story

> Study links sales reps at hospitals to higher healthcare costs. More 

Pharma News

 @FiercePharma: Chile's CFR Pharma offers $1.3B for leading South African drug maker Adcock Ingram. Will Bidvest come back? Article | Follow @FiercePharma

 @CarlyHFierce: ICYMI: King Pharmaceuticals settles for $2.2M after violating pharma emissions standards. More | Follow @CarlyHFierce

> Drugmakers to open their doc-payment books in Europe. News

> Under new scrutiny, foreign firms 'have to be careful' in China, experts say. More

> Study confirms pharma's austerity pain in Europe. Story

Drug Delivery News

 @MichaelGFierce:  Mass-produced nanoparticles for drug delivery show market potential. More | Follow @MichaelGFierce

> Avanir drops $110M on novel inhaled-delivery migraine device. News

> UVA researchers find enzyme target for glioblastoma, cancer treatment. Story

> High-dose schizophrenia treatment crosses blood-brain barrier. Read

> Alnylam reports two more positive trials in RNAi arena. More 

And Finally… Investigators at Lund University say that even a modest amount of exercise will spur positive epigenetic changes in fat cells that change the way the body stores fat. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.